Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

sipuleucel-T

- PMLiVE

NICE rejects Pfizer’s antibody drug for leukaemia

Trial shows no survival benefit from Besponsa compared to current treatment

Eli Lilly HQ

FDA fast-tracks Pfizer and Lilly’s tanezumab

The novel pain drug treats osteoarthritis and chronic low back pain

- PMLiVE

Pfizer hits accelerator on Xtandi trial in early prostate cancer

US pharma giant expects PROSPER trial results later this year

- PMLiVE

Pfizer wins EU approval for MenB vaccine Trumenba

US pharma firm’s injection can now be given to patients aged 10 and above

- PMLiVE

Pfizer gets FDA panel recommendation for biosimilar EPO

Product could be the first direct competitor to Epogen and Procrit in the US

- PMLiVE

Merck and Pfizer claim second FDA nod for cancer drug Bavencio

Analysts predict it will bring in sales of around $600m by 2020

- PMLiVE

Pfizer launches antibiotic resistance surveillance website

Designed for healthcare professional use ATLAS will cover 60 countries

Pfizer expands Healthcare Hub programme for tech startups

London, Stockholm, Sydney and Toronto hubs open their doors

- PMLiVE

Cancer Drugs Fund “may have harmed patients”

Researchers claim most CDF drugs failed to show benefits to patients

National Institute for Health and Care Excellence NICE logo

NICE turns down Opdivo for head and neck cancer

BMS’s nivolumab proves too costly for the NHS

- PMLiVE

Focus on value: A prescription for pharma

The pricing debate demands a common language to be developed

- PMLiVE

Snapchat arrives at scientific meetings

And NICE becomes the first public health body to use the platform

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links